310 results on atopic dermatitis
Primary:To compare the efficacy of abrocitinib 200 mg once daily (QD) versus dupilumab (as per label guidelines) in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD).Key SecondaryTo compare the efficacy…
To collect prospective clinical and molecular data on the phenotypical characteristics of patients with atopic dermatitis (AD) receiving standard care targeted systemic treatment.
We hypothezise that methotrexate and azathioprine will be equally effective for the treatment of severe atopic dermatitis.
Primary Objective To evaluate the safety and tolerability of topical XZ.700 in patients with mild to moderate atopic dermatitis Secondary Objectives To investigate the PD effects of XZ.700 in patients with mild to moderate atopic dermatitis To…
To explore associations between biomarkers of atopic dermatitis(AD) and:• Disease state and time course of AD,• Disease state and evolution of selected atopiccomorbid conditions,• Effectiveness of specific AD treatments.
Primary Objective• To estimate the long term safety of 100 mg and 200 mg once daily (QD) of abrocitinib with or without topical treatments in adult and adolescent subjects who previously participated in qualifying abrocitinib atopic dermatitis (AD)…
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
Dermalex eczema cream will decrease symptoms of atopic dermatitis significantly and will be superior to Unguentum leniens and Hydrocortison when used for a 6 week period
Our primary objective is to assess the relation between itch and sustained attention in 7-11 year old children with atopic dermatitis (AD). Secondary objectives are to assess the relation between itch and task-oriented behavior, to assess whether…
The purpose of this study is to investigate how safe the new compound RPT193 is when it is administered to healthy subjects. RPT193 has not been administered to humans before. It has been previously tested in the laboratory and on animals. RPT193…
The effectiveness and cost-effectiveness of treatment with systemic cyclosporine or dupilumab in children with moderate-to-severe atopic dermatitis is different for patients with low NMF (corresponding with filaggrine-gene mutation) versus children…
To assess long-term safety, tolerability and efficacy of upadacitinib in adult subjects with moderate to severe atopic dermatitis who successfully completed treatment in the M16-046 study. Efficacy will be evaluated through Week 52, and safety and…
PrimaryPart 3 - Repeated doses in atopic dermatitis (AD) patients - PDY16891* To evaluate the safety and tolerability of SAR443726 after repeated SC doses in adult participants with moderate-to-severe ADSecondaryPart 3 - Repeated doses in AD…
Primary objective:Assess the efficacy of rilzabrutinib in participants with atopic dermatitis (AD)Secondary objectives: * Assess the efficacy of rilzabrutinib at different time points* Assess the safety of rilzabrutinib
The objective of the study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult subjects with moderate to severe AD who are candidates for systemic therapy.
The objective of the study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult subjects with moderate to severe AD who are candidates for systemic therapy.
The primary aim is to study the effect of treatment of severe AD patients with Myfortic on DNA-repair after irradiation with UVB.A secondary aim is to study the effect of treatment of severe AD patients on atopic status, measured as total IgE and…
To determine whether a potent topical CS is more effective than a mild topical CS in the treatment of children with a moderate flare-up of atopic dermatitis in primary care on short and long term.
The primary objective of the study is to evaluate the efficacy of REGN3500monotherapy compared with placebo treatment in adult patients withmoderate-to-severe atopic dermatitis (AD).The secondary objectives of the study are:* To evaluate the…
We hypothesize that atopiform dermatitis is a separate entity with specific characteristics, which needs recognition in order to be diagnosed and treated appropriately.